Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124881452 | 12488145 | 2 | F | 201601 | 20160729 | 20160622 | 20160819 | PER | US-PFIZER INC-2016288586 | PFIZER | 27.00 | YR | M | Y | 109.00000 | KG | 20160819 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124881452 | 12488145 | 1 | PS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 30 ML, DAILY | N12193 | 21106 | 30 | ML | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | ||||||
124881452 | 12488145 | 2 | SS | SOMAVERT | PEGVISOMANT | 1 | 21106 | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | |||||||||||
124881452 | 12488145 | 3 | C | SYNTHROID | LEVOTHYROXINE SODIUM | 1 | Oral | 0.1 MG, 1X/DAY (IN THE MORNING) | 0 | .1 | MG | TABLET | QD | ||||||
124881452 | 12488145 | 4 | C | HYDROCORTISONE. | HYDROCORTISONE | 1 | Oral | 30 MG, DAILY (20MG, IN THE MORNING, AND 10MG IN THE EVENING) | 0 | 30 | MG | TABLET | |||||||
124881452 | 12488145 | 5 | C | OCTREOTIDE. | OCTREOTIDE | 1 | 120 MG, MONTHLY | 0 | 120 | MG | INJECTION | /month | |||||||
124881452 | 12488145 | 6 | C | OCTREOTIDE. | OCTREOTIDE | 1 | 120 MG, MONTHLY | 0 | 120 | MG | INJECTION | /month | |||||||
124881452 | 12488145 | 7 | C | TESTOSTERONE. | TESTOSTERONE | 1 | 0.5 ML, WEEKLY | 0 | .5 | ML | INJECTION | /wk |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
124881452 | 12488145 | 1 | Acromegaly |
124881452 | 12488145 | 2 | Insulin-like growth factor increased |
124881452 | 12488145 | 3 | Hypothyroidism |
124881452 | 12488145 | 4 | Adrenal insufficiency |
124881452 | 12488145 | 5 | Acromegaly |
124881452 | 12488145 | 7 | Hypogonadism |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
124881452 | 12488145 | Drug effect incomplete | |
124881452 | 12488145 | Fatigue | |
124881452 | 12488145 | Intentional product misuse | |
124881452 | 12488145 | Peripheral swelling | |
124881452 | 12488145 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
124881452 | 12488145 | 1 | 2013 | 0 | ||
124881452 | 12488145 | 3 | 2013 | 0 | ||
124881452 | 12488145 | 4 | 2013 | 0 | ||
124881452 | 12488145 | 5 | 2013 | 0 | ||
124881452 | 12488145 | 6 | 2015 | 0 | ||
124881452 | 12488145 | 7 | 2013 | 0 |